Literature DB >> 24613228

Consensus on cerebral involvement in myotonic dystrophy: workshop report: May 24-27, 2013, Ferrere (AT), Italy.

E Bugiardini1, G Meola2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 24613228     DOI： 10.1016/j.nmd.2014.01.013

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN： 0960-8966            Impact factor:   4.296


× No keyword cloud information.
  19 in total

1.  Medication adherence in patients with myotonic dystrophy and facioscapulohumeral muscular dystrophy.

Authors:  Bryan P Fitzgerald; Kelly M Conn; Joanne Smith; Andrew Walker; Amy L Parkhill; James E Hilbert; Elizabeth A Luebbe; Richard T Moxley
Journal:  J Neurol       Date:  2016-10-12       Impact factor: 4.849

2.  Brain MRI abnormalities in the adult form of myotonic dystrophy type 1: A longitudinal case series study.

Authors:  Renata Conforti; Mario de Cristofaro; Adriana Cristofano; Barbara Brogna; Angela Sardaro; Gioacchino Tedeschi; Sossio Cirillo; Alfonso Di Costanzo
Journal:  Neuroradiol J       Date:  2016-01-11

Review 3.  Myotonic dystrophy.

Authors:  Charles A Thornton
Journal:  Neurol Clin       Date:  2014-06-06       Impact factor: 3.806

4.  Frontostriatal dysexecutive syndrome: a core cognitive feature of myotonic dystrophy type 2.

Authors:  Stojan Peric; Gorana Mandic-Stojmenovic; Elka Stefanova; Dusanka Savic-Pavicevic; Jovan Pesovic; Vera Ilic; Valerija Dobricic; Ivana Basta; Dragana Lavrnic; Vidosava Rakocevic-Stojanovic
Journal:  J Neurol       Date:  2014-10-28       Impact factor: 4.849

5.  Evaluation of CNS involvement in myotonic dystrophy type 1 and type 2 by transcranial sonography.

Authors:  Christos Krogias; Barbara Bellenberg; Christian Prehn; Ruth Schneider; Saskia H Meves; Ralf Gold; Carsten Lukas; Christiane Schneider-Gold
Journal:  J Neurol       Date:  2014-11-11       Impact factor: 4.849

6.  Drug resistant focal epilepsy in a patient with myotonic dystrophy type 2: casual or causal association?

Authors:  L Giuliano; V Sofia; R Cardani; G Meola; M Zappia
Journal:  Neurol Sci       Date:  2016-05-25       Impact factor: 3.307

7.  Patient-Reported Impact of Symptoms in Myotonic Dystrophy Type 2 (PRISM-2).

Authors:  Chad Heatwole; Nicholas Johnson; Rita Bode; Jeanne Dekdebrun; Nuran Dilek; James E Hilbert; Elizabeth Luebbe; William Martens; Michael P McDermott; Christine Quinn; Nan Rothrock; Charles Thornton; Barbara G Vickrey; David Victorson; Richard T Moxley
Journal:  Neurology       Date:  2015-11-18       Impact factor: 9.910

8.  Cholesterol-functionalized DNA/RNA heteroduplexes cross the blood-brain barrier and knock down genes in the rodent CNS.

Authors:  Tetsuya Nagata; Chrissa A Dwyer; Kie Yoshida-Tanaka; Kensuke Ihara; Masaki Ohyagi; Hidetoshi Kaburagi; Haruka Miyata; Satoe Ebihara; Kotaro Yoshioka; Takashi Ishii; Kanjiro Miyata; Kenichi Miyata; Berit Powers; Tomoko Igari; Syunsuke Yamamoto; Naoto Arimura; Hideki Hirabayashi; Toshiki Uchihara; Rintaro Iwata Hara; Takeshi Wada; C Frank Bennett; Punit P Seth; Frank Rigo; Takanori Yokota
Journal:  Nat Biotechnol       Date:  2021-08-12       Impact factor: 68.164

9.  Cortical and Subcortical Grey and White Matter Atrophy in Myotonic Dystrophies Type 1 and 2 Is Associated with Cognitive Impairment, Depression and Daytime Sleepiness.

Authors:  Christiane Schneider-Gold; Barabara Bellenberg; Christian Prehn; Christos Krogias; Ruth Schneider; Jan Klein; Ralf Gold; Carsten Lukas
Journal:  PLoS One       Date:  2015-06-26       Impact factor: 3.240

10.  High frequency of gastrointestinal manifestations in myotonic dystrophy type 1 and type 2.

Authors:  James E Hilbert; Richard J Barohn; Paula R Clemens; Elizabeth A Luebbe; William B Martens; Michael P McDermott; Amy L Parkhill; Rabi Tawil; Charles A Thornton; Richard T Moxley
Journal:  Neurology       Date:  2017-08-30       Impact factor: 9.910
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.